Swedish biotech company Gesynta Pharma AB has secured $27 million in a Series B financing round led by Innovestor Life Science in Finland.

Piper Sandler downgraded Kite Realty Group (NYSE:KRG) shares to Neutral from Overweight in a recent note as "we view the ...

Sales of the firm's cell therapy franchise grew modestly in the fourth quarter amid competing product launches and overall slow uptake within the class.

Financial writer recommends buying Kite Realty post-2021 merger, citing strong balance sheet, tenant diversification, and ...

Marking World Cancer Day 2025, this week's Executive Q&A is with Diego Santoro, General Manager & Head of International ...

Kite, a Gilead Sciences company, will share four posters that add to the growing body of evidence to support the clinical use of its chimeric antigen receptor (CAR) T-cell therapy portfolio, at the ...

Sartorius Stedim Biotech SA / Key word (s): Dividend Board of Directors of Sartorius Stedim Biotech resolves to propose dividend of 0.69 euros per share to Annual Shareholders’ Meeting 07-Feb-2025 ...

Telefónica Tech has been ranked as the global leader in managed IoT connectivity by Kaleido Intelligence in its "Connectivity Vendor Hub: Compet ...

AmplifyBio, a leading preclinical CRO and CDMO played a pivotal role in shaping discussions at Phacilitate’s Advanced Therapy Week, held January 20-23 in Dallas, Texas. As usual, the event brought ...

Kite Pharma’s share price has dived after it emerged that a patient has died from cerebral oedema while being treated with its CAR-T therapy, KTE-C19. Investors were spooked by the news ...

A California federal district court denied Gilead Sciences, Inc. and Kite Pharma, Inc.’s motion to dismiss unpaid overtime claims under the Fair Labor Standards Act of two cell therapy specialists ...

A new leadership team helmed by Johnson & Johnson alum Paul Stoffels was entrenching Galapagos into cell therapy, but Gilead already had this space covered with Kite Pharma, which it acquired in 2017 ...